These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 20471477)

  • 1. Murine models of Alzheimer's disease and their use in developing immunotherapies.
    Wisniewski T; Sigurdsson EM
    Biochim Biophys Acta; 2010 Oct; 1802(10):847-59. PubMed ID: 20471477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models.
    Wisniewski T; Boutajangout A
    Brain Struct Funct; 2010 Mar; 214(2-3):201-18. PubMed ID: 20012091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy for Alzheimer's disease.
    Wisniewski T; Goñi F
    Biochem Pharmacol; 2014 Apr; 88(4):499-507. PubMed ID: 24412277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination as a therapeutic approach to Alzheimer's disease.
    Wisniewski T; Boutajangout A
    Mt Sinai J Med; 2010; 77(1):17-31. PubMed ID: 20101719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advancements toward therapeutic vaccines against Alzheimer's disease.
    Herline K; Drummond E; Wisniewski T
    Expert Rev Vaccines; 2018 Aug; 17(8):707-721. PubMed ID: 30005578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic vaccination with anti-oligomeric monoclonal antibodies improves cognitive function by reducing Aβ deposition and tau pathology in 3xTg-AD mice.
    Rasool S; Martinez-Coria H; Wu JW; LaFerla F; Glabe CG
    J Neurochem; 2013 Aug; 126(4):473-82. PubMed ID: 23672786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunomodulation targeting abnormal protein conformation reduces pathology in a mouse model of Alzheimer's disease.
    Goñi F; Prelli F; Ji Y; Scholtzova H; Yang J; Sun Y; Liang FX; Kascsak R; Kascsak R; Mehta P; Wisniewski T
    PLoS One; 2010 Oct; 5(10):e13391. PubMed ID: 20967130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy to improve cognition and reduce pathological species in an Alzheimer's disease mouse model.
    Herline K; Prelli F; Mehta P; MacMurray C; Goñi F; Wisniewski T
    Alzheimers Res Ther; 2018 Jun; 10(1):54. PubMed ID: 29914551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Testing a MultiTEP-based combination vaccine to reduce Aβ and tau pathology in Tau22/5xFAD bigenic mice.
    Davtyan H; Hovakimyan A; Kiani Shabestari S; Antonyan T; Coburn MA; Zagorski K; Chailyan G; Petrushina I; Svystun O; Danhash E; Petrovsky N; Cribbs DH; Agadjanyan MG; Blurton-Jones M; Ghochikyan A
    Alzheimers Res Ther; 2019 Dec; 11(1):107. PubMed ID: 31847886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer's disease pathogenesis.
    Boche D; Denham N; Holmes C; Nicoll JA
    Acta Neuropathol; 2010 Sep; 120(3):369-84. PubMed ID: 20632020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction of amyloid beta by Aβ3-10-KLH vaccine also decreases tau pathology in 3×Tg-AD mice.
    Zhang HY; Zhu K; Meng Y; Ding L; Wang JC; Yin WC; Yan Y; Cao YP
    Brain Res Bull; 2018 Sep; 142():233-240. PubMed ID: 30077729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibrillar Aβ triggers microglial proteome alterations and dysfunction in Alzheimer mouse models.
    Sebastian Monasor L; Müller SA; Colombo AV; Tanrioever G; König J; Roth S; Liesz A; Berghofer A; Piechotta A; Prestel M; Saito T; Saido TC; Herms J; Willem M; Haass C; Lichtenthaler SF; Tahirovic S
    Elife; 2020 Jun; 9():. PubMed ID: 32510331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developing therapeutic vaccines against Alzheimer's disease.
    Wisniewski T; Drummond E
    Expert Rev Vaccines; 2016; 15(3):401-15. PubMed ID: 26577574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel immunological approaches for the treatment of Alzheimer's disease.
    Sabharwal P; Wisniewski T
    Zhongguo Xian Dai Shen Jing Ji Bing Za Zhi; 2014; 14(3):139-151. PubMed ID: 25429302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Active full-length DNA Aβ
    Rosenberg RN; Fu M; Lambracht-Washington D
    Alzheimers Res Ther; 2018 Nov; 10(1):115. PubMed ID: 30454039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Developing novel immunogens for a safe and effective Alzheimer's disease vaccine.
    Lemere CA
    Prog Brain Res; 2009; 175():83-93. PubMed ID: 19660650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-β-sheet conformation monoclonal antibody reduces tau and Aβ oligomer pathology in an Alzheimer's disease model.
    Goñi F; Martá-Ariza M; Herline K; Peyser D; Boutajangout A; Mehta P; Drummond E; Prelli F; Wisniewski T
    Alzheimers Res Ther; 2018 Jan; 10(1):10. PubMed ID: 29378642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular and functional signatures in a novel Alzheimer's disease mouse model assessed by quantitative proteomics.
    Kim DK; Park J; Han D; Yang J; Kim A; Woo J; Kim Y; Mook-Jung I
    Mol Neurodegener; 2018 Jan; 13(1):2. PubMed ID: 29338754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunomodulation targeting of both Aβ and tau pathological conformers ameliorates Alzheimer's disease pathology in TgSwDI and 3xTg mouse models.
    Goñi F; Herline K; Peyser D; Wong K; Ji Y; Sun Y; Mehta P; Wisniewski T
    J Neuroinflammation; 2013 Dec; 10():150. PubMed ID: 24330773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
    Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
    Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.